The World Health Organization has released a draft guidance on Quality Risk Management (QRM) designed to support science-based, patient-focused decisions across the entire medicine lifecycle—from research and development and material sourcing through manufacturing, testing, storage, and distribution. The draft is organized into six main sections covering principles, glossary, the QRM process itself, application within pharmaceutical companies, use by regulatory authorities, and supporting tools such as Preliminary Hazard Analysis and statistical methods. Public comments are invited through mid-November 2026.
The document emphasizes that the level of effort and documentation should be proportionate to the risk, decisions must be informed by product and process knowledge, and subjectivity should be reduced through structured approaches. It addresses QRM in training, responsibilities, development, validation, commercial manufacturing, quality systems, inspection planning, CAPA review, and dossier assessment.
**Why it matters**
Effective QRM moves organizations from reactive problem-solving to proactive risk identification and control. It strengthens decision-making consistency, supports regulatory interactions, and ultimately protects patients by focusing resources where they deliver the greatest quality impact. For companies operating under ICH Q9 principles or equivalent frameworks, this draft offers additional practical structure, especially for organizations building or maturing their risk management systems.
**Insights**
The draft reinforces that QRM is not a one-time exercise or a compliance checkbox. Integration into daily operations—staff competency, change control, deviation management, and supplier oversight—is essential. Proportionality is key: high-risk activities (sterile processing, critical quality attributes) warrant more rigorous tools and documentation than lower-risk ones. Reducing subjectivity through cross-functional input and data-driven methods improves reliability. Regulatory authorities are also expected to apply risk-based approaches in their oversight, which may influence inspection frequency and focus.
Companies should evaluate how their current QRM procedures align with the draft’s process steps (initiation, assessment, control, review, communication) and tool recommendations. Early engagement with the comment period can help shape final guidance while preparing internal systems.
**Practical next steps**
Map existing QRM activities against the draft’s structure and identify gaps in documentation, training, or tool use. Update risk assessment templates to emphasize product/process knowledge and clear residual risk acceptance. Train multidisciplinary teams on proportional application and bias reduction. Review how QRM outputs feed into validation, change control, and management review. Consider piloting enhanced approaches on a high-risk process and measuring decision quality and efficiency.
**Related keywords**
WHO Quality Risk Management draft guidance, ICH Q9 principles, pharmaceutical lifecycle risk management, risk-based decision making, contamination control strategy QRM, quality system integration, proportional documentation, science-based risk assessment, regulatory inspection planning, patient protection quality
**Hashtags**
#QualityRiskManagement #WHOGuidance #ICHQ9 #GMP #PharmaceuticalQuality #RiskBasedApproach #QualityCulture #RegulatoryCompliance
Post a Comment